Nevirapine (NVP) — Competitive Intelligence Brief

Nevirapine (NVP) (Nevirapine (NVP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease / Virology.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Nevirapine (NVP) (Nevirapine (NVP)) — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nevirapine (NVP) TARGET	Nevirapine (NVP)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Tenofovir/Emtricitabine and efavirenz	Tenofovir/Emtricitabine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
TAF/FTC	TAF/FTC	Göteborg University	marketed	Nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class